DBA/2 and C57B1/6 mice were infected intraperitoneally with two different strains of herpes simplex virus type 1, HSV-1 ANG and HSV-1 WAL. Unlike HSV-1 WAL, HSV-1 ANG was apathogenic by this mode of infection. Furthermore, infection with HSV-1 ANG protected mice of both inbred strains against infections with lethal doses of pathogenic HSV-1 WAL. This protection was observed when the apathogenic virus was given with the pathogenic virus or 4 to 24 h before it.
HSV-1 WAL (2 x 106 p.f.u.)* 8/10 HSV-1 ANG LP5 (6 x 106 p.f.u.) 0/10 HSV-1 WAL(2 x 106 p.f.u.) + 1/10 HSV-I ANG LP5 (6 x 106 p.f,u.)
DBA/2 HSV-1 WAL (2 × 103 p.f.u.) HSV-1 ANG LP5 (6 × l0 s p.f.u.) HSV-1 WAL (2 x 103 p.f.u.) + HSV-1 ANG LP5 (6 × 106p.f.u.)
10/10 0/10 3/10 * Infectious dose of the respective virus is indicated in parentheses. Time at which the mice were injected with HSV-1 ANG relative to the injection with HSV-1 WAL. $ The virus stock had been u.v.-irradiated as previously described (Schr6der & Urbaczka, 1978) , leading to a decrease in its infectivity by about 6 log10 units.
§ Volume equivalents of the irradiated virus corresponding to a dose of 2 × 106 p.f.u, of the unirradiated HSV-1 WAL were used. Table 1 shows the pathogenicity of HSV-I WAL for both C57BL/6 and DBA/2 mice. In contrast, HSV-1 ANG did not kill the mice even when, as in the case of DBA/2 mice, given at a dose much higher than a lethal dose of HSV-1 WAL.
Simultaneous infection of mice with HSV-I WAL and HSV-1 ANG LP5 resulted in a decreased mortality for both mouse strains as compared to infections with HSV-1 WAL alone (Table 1) . From these data we conclude that infection with HSV-1 ANG LP5 protects the mice against death due to infection by the HSV-1 WAL virus strain. Both HSV-1 WAL and HSV-1 ANG LP5 used for these infections had been propagated in vitro on RC-37 cells.
In Table 2 experiments are listed which demonstrate the protective effect in DBA/2 mice of HSV-1 ANG preparations against an infection with HSV-1 WAL.
The protection observed was not influenced by the host cells, on which the virus had been passaged in vitro, or by the presence of defective and interfering particles in HSV-1 ANG ) showed that media of virus preparations that were freed of virions by ultracentrifugation and sonicates derived from uninfected cells had no protective effect. DBA/2 mice appeared to be equally well protected regardless of whether the HSV-1 ANG were given simultaneously with HSV-1 WAL or 4 or 24 h before HSV-1 WAL infection. The dose of infectious HSV-1 ANG needed for protection was 2 to 3 log~0 units higher than the dose of HSV-1 WAL required for killing the mice (data not shown). Furthermore, protection of the mice against lethal infection with HSV-1 WAL was observed also when the apathogenic HSV-1 ANG was injected intravenously (i.v.; Table 2 , expt. 5). In contrast, u.v.-irradiated HSV-1 WAL was not protective when given 24 h before infection with infectious HSV-1 WAL (Table 2, expt. 5).
HP18. Further controls (not included in the table
It is not known why HSV-1 ANG is apathogenic and why it protects against the pathogenic virus strain. Obviously, however, there is no role of defective and interfering virus particles in protection. Preliminary data suggest that the various strains of HSV-1 ANG do not induce serum interferon more efficiently than HSV-1 WAL (H. Kirchner, R. Zawatzky & C. H. Schr6der, unpublished data) . Furthermore, when HSV-1 ANG was given 24 h before HSV-1 WAL and serum interferon measured there was no increase compared to the controls that received only HSV-1 WAL. HSV-1 ANG also was not a better inducer of interferon at the local injection site, i.e. when the peritoneal exudate was investigated. There are many factors probably involved in the defence against primary virus infection. Most prominent are the macrophages (Mogensen, 1979; Morahan & Morse, 1979 ) but more recent evidence indicates that natural killer (NK) cells may also be of importance (Welsh, 1978) . The most recent data from our laboratory suggest that HSV-1 ANG is a better stimulant of NK cell activity than HSV-1 WAL (H. Engler, H. Kirchner & C. H. Schr6der, unpublished data 
